Tag: mortality

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea

INSIDE INFORMATION
REGULATED INFORMATION

Bluejay Diagnostics Provides Second Quarter Business and Corporate Update

ACTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced financial results for the quarter ended June 30, 2025, and provided an update on its Symphony IL-6 test program and key operational milestones.

Great-West Lifeco reports record base earnings and announces intention for additional $500 million in share buybacks

TSX:GWO Great-West Lifeco Inc.'s Quarterly Report to Shareholders for the second quarter of 2025, including its Management's Discussion and Analysis (MD&A) and consolidated financial statements...

JAMA Surgery Study Confirms Diagnostic Value of Cizzle Bio’s DEX-G2 Blood Test For Early Detection of Gastric Cancer

SAN ANTONIO, Aug. 5, 2025 /PRNewswire/ -- A groundbreaking multicenter clinical study published on July 30 in JAMA Surgery confirms the powerful diagnostic performance...

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (“CSPC”) for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. Madrigal plans to initiate clinical development in the first half of 2026.

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections

Allschwil, Switzerland, July 29, 2025

Vaccines: Mythology, Ideology, and Reality, New Book by John Leake and Peter A. McCullough

NEW YORK, July 28, 2025 /PRNewswire/ -- Vaccines: Mythology, Ideology, and Reality tells the story of immunizations and the celebrated men who developed it with...

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.

July 28, 2025
News Release

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC). NPC is an ultra-rare, neurological disease caused by genetic mutations that result in lipid accumulation in cells, leading to visceral, neurological, and psychiatric symptoms. Arimoclomol is the only treatment shown to directly target the underlying pathology of NPC by increasing gene expression for improved lipid clearance. Arimoclomol for the treatment of NPC has been designated as an Orphan Medicinal Product by the EMA. Arimoclomol is marketed in the U.S. under the brand name MIPLYFFA®.

Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer

HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been...

4TEEN4 Doses First Patient in Phase 1b/2a Trial of Procizumab, a Monoclonal Antibody Targeting the Biological Driver of Shock

Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal antibody, procizumab, in patients with shock caused primarily by cardiogenic events. Shock is a life-threatening condition characterized by a sudden breakdown in circulatory function due to end-stage disease or acute events, which often leads to organ failure. With only symptomatic treatment options available, shock is associated with a high mortality rate of over 50%. The Phase 1b/2a trial is designed to identify a target dose for procizumab in preparation for further clinical development. In addition, the trial will provide signals of efficacy. In a Phase 1 study in healthy volunteers, procizumab was well tolerated.

Somatus Surpasses 500,000 Patients Actively Under Management Across All 50 States and DC

Value-based kidney care leader expands capabilities in CHF care management, commercial self-insured populations, and AI-driven disease identification and payment integrity services MCLEAN, Va., July 22,...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsMortality

Tennessee American Water Proudly Recognizes American Water Charitable Foundation 2026 Water and Environment Grantees

Top Two Spots in American Banker’s 50 Top Innovators in Finance Awarded to CEOs of Vantage Bank and Custodia, Hazel Network’s Co-Founders

Vinitaly debuts in Cape Town to strengthen Italian wine presence in Africa

Tag: mortality

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea

Bluejay Diagnostics Provides Second Quarter Business and Corporate Update

Great-West Lifeco reports record base earnings and announces intention for additional $500 million in share buybacks

JAMA Surgery Study Confirms Diagnostic Value of Cizzle Bio’s DEX-G2 Blood Test For Early Detection of Gastric Cancer

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections

Vaccines: Mythology, Ideology, and Reality, New Book by John Leake and Peter A. McCullough

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer

4TEEN4 Doses First Patient in Phase 1b/2a Trial of Procizumab, a Monoclonal Antibody Targeting the Biological Driver of Shock

Somatus Surpasses 500,000 Patients Actively Under Management Across All 50 States and DC

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us